Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bug

Showing results (311-320 of 320) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 320 results.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Plos One|September 15, 2009
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasmsJose I Martin-Subero, Ole Ammerpohl, Marina Bibikova, et al.
Cells|December 11, 2019
Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 PatientsHalvard Bonig, Zyrafete Kuçi, Selim Kuçi, et al.
The Lancet. Haematology|April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood|July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>-Internal Tandem Duplication Mutation (SORMAIN)Andreas Burchert, Gesine Bug, Lea V Fritz, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
Plos One|April 30, 2016
The Ontology for Biomedical InvestigationsAnita Bandrowski, Ryan Brinkman, Mathias Brochhausen, et al.
Blood|July 15, 2024
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)Katja Sockel, Annika Neu, Maren Goeckenjan, et al.
Leukemia|August 1, 2015
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyR Zeiser, A Burchert, C Lengerke, et al.
Pageof 32

Showing results (311-320 of 320) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 320 results.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Plos One|September 15, 2009
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasmsJose I Martin-Subero, Ole Ammerpohl, Marina Bibikova, et al.
Cells|December 11, 2019
Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 PatientsHalvard Bonig, Zyrafete Kuçi, Selim Kuçi, et al.
The Lancet. Haematology|April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood|July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>-Internal Tandem Duplication Mutation (SORMAIN)Andreas Burchert, Gesine Bug, Lea V Fritz, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
Plos One|April 30, 2016
The Ontology for Biomedical InvestigationsAnita Bandrowski, Ryan Brinkman, Mathias Brochhausen, et al.
Blood|July 15, 2024
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)Katja Sockel, Annika Neu, Maren Goeckenjan, et al.
Leukemia|August 1, 2015
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyR Zeiser, A Burchert, C Lengerke, et al.
Pageof 32